Zaqbo Surpasses 10 Billion Won in Monthly Prescription Sales Two Years After Launch, Joins Ranks of Domestic P-CAB Blockbusters
- Input
- 2026-11-10 09:04:18
- Updated
- 2026-11-10 09:04:18

[Financial News] The domestically developed P-CAB drug Zaqbo (active ingredient: Zastaprazan) has joined the ranks of blockbuster drugs just two years after its launch. Monthly outpatient prescription sales exceeded 10 billion won for the first time.
According to UBIST, a pharmaceutical market research firm, outpatient prescription sales of Jeil Pharmaceutical Co., Ltd.’s Zaqbo totaled 10.3 billion won in October 2026. Under the criteria in place before the drug price flexibility system took effect, that would rank it among the top 10 products in South Korea’s ethical drug (ETC) market.
Zaqbo is seen as moving beyond the initial market-entry stage and establishing itself as a major product representing South Korea’s ethical drug market. Industry observers are paying attention to its rapid growth—surpassing the 10-billion-won monthly mark in a short period—as well as its commercial competitiveness.
Zaqbo is South Korea’s 37th domestically developed novel drug, developed by Onconic Therapeutics, Jeil Pharmaceutical Co., Ltd.’s drug development subsidiary, and belongs to the P-CAB (potassium-competitive gastric acid secretion inhibitor) class. It has continued to expand its foothold in the prescription market, with strengths including a faster onset of action than existing PPIs (proton pump inhibitors), a longer half-life that helps control nighttime gastric acid secretion, and the ability to be taken regardless of meals.
Since the launch, Jeil Pharmaceutical Co., Ltd. has focused on expanding its prescription base through active sales and marketing. Zaqbo gained a foothold in the market through co-promotion with Dong-A ST, a major player in the digestive disease field. After adding gastric ulcer as an indication last June, the company further expanded the product line by launching an orally disintegrating tablet in January this year that is easier to take.
The company is also continuing to expand the drug’s indications. In addition to its currently approved indications—erosive gastroesophageal reflux disease and gastric ulcer—Zaqbo is undergoing Phase 3 trials for non-erosive gastroesophageal reflux disease, Helicobacter pylori eradication therapy, maintenance treatment for erosive gastroesophageal reflux disease, and prevention of peptic ulcers caused by nonsteroidal anti-inflammatory drugs (NSAIDs), among others.
The company is also accelerating commercialization overseas. Zaqbo has entered 28 countries, including China and India. In India, it received its first overseas product approval in August as a treatment for erosive gastroesophageal reflux disease. In China, its partner Livzon Pharmaceutical is pursuing product approval for the treatment of erosive gastroesophageal reflux disease while also advancing Phase 3 trials of Helicobacter pylori eradication therapy and an injectable formulation, seeking to expand the drug’s indications and dosage forms.
A Jeil Pharmaceutical Co., Ltd. representative said, “For a domestically developed novel drug to surpass 10 billion won in monthly outpatient prescription sales just two years after launch and enter the top 10 of the overall ethical drug market is a meaningful achievement, showing that Zaqbo has established itself as a major treatment option in South Korea’s P-CAB market.” The representative added, “We will continue to strengthen the product’s competitiveness, including by securing additional indications, broaden its prescribing reach, and raise Zaqbo’s value in global markets as well.”
[email protected] Jung Myung-jin, reporter